drugset / Trial / NCT07546630
Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma
NaSequentialOpen-labelTreatment
Summary
This is a single arm study to evaluate the safety and efficacy of Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell therapy for Relapsed/Refractory B-Cell Lymphoma
Timeline
- Start
- 2026-04-30
- Primary completion
- 2028-05-01
- Completion
- 2029-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/CD20 Tandem Dual CAR-T | Cell therapy | 2 cells/kg | Intravenous |
| Subject | CD19/CD20 Tandem Dual CAR-T | Cell therapy | 4 cells/kg | Intravenous |
| Subject | CD19/CD20 Tandem Dual CAR-T | Cell therapy | 6 cells/kg | Intravenous |